



**United States Department of State**

***Washington, D.C. 20520***

November 27, 2024

Case No. FL-2022-00062

Mr. Gary Ruskin  
U.S. Right to Know  
4096 Piedmont Avenue, #963  
Oakland, CA 94611

Dear Mr. Ruskin:

As we noted in our letter dated October 18, 2024, we are processing your request for material under the Freedom of Information Act (“FOIA”), 5 U.S.C. § 552. The Department of State (“Department”) has identified one additional responsive record subject to the FOIA. We have determined that this record may be released in part.

An enclosure explains the FOIA exemptions and other grounds for withholding material. Where we have made redactions, the applicable FOIA exemptions are marked on the record. Where applicable, the Department has considered the foreseeable harm standard when reviewing the record and applying FOIA exemptions. All non-exempt material that is reasonably segregable from the exempt material has been released and is enclosed.

We will keep you informed as your case progresses. If you have any questions, your attorney may contact Assistant United States Attorney Stephanie Johnson at [stephanie.johnson5@usdoj.gov](mailto:stephanie.johnson5@usdoj.gov) or (202) 252-7874. Please refer to the case number, FL-2022-00062, and the civil action number, 22-cv-01130, in all correspondence about this case.

Sincerely,

A handwritten signature in cursive script that reads "Avery Bullard".

Avery D. Bullard  
Supervisory Government Information Specialist  
Litigation and Appeals Office

Enclosures: As stated.

## The Freedom of Information Act (5 USC 552)

### FOIA Exemptions

- (b)(1) Information specifically authorized by an executive order to be kept secret in the interest of national defense or foreign policy. Executive Order 13526 includes the following classification categories:
- 1.4(a) Military plans, systems, or operations
  - 1.4(b) Foreign government information
  - 1.4(c) Intelligence activities, sources or methods, or cryptology
  - 1.4(d) Foreign relations or foreign activities of the US, including confidential sources
  - 1.4(e) Scientific, technological, or economic matters relating to national security, including defense against transnational terrorism
  - 1.4(f) U.S. Government programs for safeguarding nuclear materials or facilities
  - 1.4(g) Vulnerabilities or capabilities of systems, installations, infrastructures, projects, plans, or protection services relating to US national security, including defense against transnational terrorism
  - 1.4(h) Weapons of mass destruction
- (b)(2) Related solely to the internal personnel rules and practices of an agency
- (b)(3) Specifically exempted from disclosure by statute (other than 5 USC 552), for example:
- |                |   |
|----------------|---|
| ARMSEXP        | Arms Export Control Act, 50a USC 2411(c)                    |
| CIA PERS/ORG   | Central Intelligence Agency Act of 1949, 50 USC 403(g)      |
| EXPORT CONTROL | Export Administration Act of 1979, 50 USC App. Sec. 2411(c) |
| FS ACT         | Foreign Service Act of 1980, 22 USC 4004                    |
| INA            | Immigration and Nationality Act, 8 USC 1202(f), Sec. 222(f) |
| IRAN           | Iran Claims Settlement Act, Public Law 99-99, Sec. 505      |
- (b)(4) Trade secrets and confidential commercial or financial information
- (b)(5) Interagency or intra-agency communications forming part of the deliberative process, attorney-client privilege, or attorney work product
- (b)(6) Personal privacy information
- (b)(7) Law enforcement information whose disclosure would:
- (A) interfere with enforcement proceedings
  - (B) deprive a person of a fair trial
  - (C) constitute an unwarranted invasion of personal privacy
  - (D) disclose confidential sources
  - (E) disclose investigation techniques
  - (F) endanger life or physical safety of an individual
- (b)(8) Prepared by or for a government agency regulating or supervising financial institutions
- (b)(9) Geological and geophysical information and data, including maps, concerning wells

### Other Grounds for Withholding

- NR Material not responsive to a FOIA request excised with the agreement of the requester

**From:** "Wright, Janey F" (b)(6)  
 Asher, David (b)(6);  
 Jih, Rongsong (b)(6);  
 Pease, Michael (b)(6);  
**To:** DiNanno, Thomas G (b)(6);  
 Feith, David (b)(6);  
 Gibbs, Jeffrey J (b)(6);  
 Couch, Johnny N (b)(6)

**Subject:** RE: Initial analysis of Baric emails: May/June US-China VTC's on COVID-19 (SBU)

**Date:** Mon, 28 Dec 2020 13:06:21 +0000

I'm in the office.



**Janey Wright**

Chief of Staff  
 Bureau of Arms Control, Verification and Compliance  
 U.S. Department of State  
 HST Room S950

Office: 202.647.8956

Cell: (b)(6)

OpenNet: (b)(6)  
 ClassNet:  
 JWICS:

**From:** Asher, David (b)(6)  
**Sent:** Sunday, December 27, 2020 9:55 PM  
**To:** Jih, Rongsong (b)(6); Pease, Michael (b)(6); DiNanno, Thomas G (b)(6); Feith, David (b)(6); Gibbs, Jeffrey J (b)(6); Couch, Johnny N (b)(6)  
**Cc:** Wright, Janey F (b)(6)  
**Subject:** Re: Initial analysis of Baric emails: May/June US-China VTC's on COVID-19 (SBU)

Janey, If you happen to go in tomorrow, (b)(5)

(b)(5)

(b)(7)(E)

on Tuesday to facilitate. David

---

**From:** Asher, David (b)(6)

**Sent:** Sunday, December 27, 2020 9:37 PM

**To:** Jih, Rongsong (b)(6); Pease, Michael (b)(6); DiNanno, Thomas G (b)(6); Feith, David (b)(6); Gibbs, Jeffrey J (b)(6);

Couch, Johnny N (b)(6)

**Cc:** Wright, Janey

**Subject:** Re: Initial analysis of Baric emails: May/June US-China VTC's on COVID-19

(b)(5)

---

**From:** Jih, Rongsong (b)(6) >

**Sent:** Sunday, December 27, 2020 8:54 PM

**To:** Asher, David (b)(6); Pease, Michael (b)(6); DiNanno, Thomas G (b)(6); Feith, David (b)(6); Gibbs, Jeffrey J (b)(6);

Couch, Johnny N (b)(6)

**Cc:** Wright, Janey F (b)(6); Jih, Rongsong (b)(6)

**Subject:** Re: Initial analysis of Baric emails: May/June US-China VTC's on COVID-19

Under **WIV's Microbial Resources and Bioinformatics Research Center**, there are 6 groups:

1. Virus Resources and Biotechnology Subject Group (病毒资源与生物技术学科组),
2. Applied Microbiology and Genetic Engineering Subject Group (应用微生物与基因工程学科组),
3. System Virology Group (系统病毒学学科组),
4. Insect Virus Genetic Engineering Group (昆虫病毒基因工程学科组),
5. Molecular Virology and Bioengineering Technology Group (分子病毒学及生物工程技术学科组),

**6. Arbovirus Vector Control Subject Group (虫媒病毒媒介控制学科组, headed by Yuan Zhi-Ming)**

To carry out arbovirus detection and biological control of vector mosquitoes.

Focuses on the rapid detection of dengue virus, Japanese encephalitis virus and West Nile virus and the interaction between the virus and the host, mosquito pathogenic microorganisms and their genetic resources, microbial genomics and comparative genomics, and mosquito toxin protein characteristics and the mode of action, the genetic improvement of mosquito-killing bacteria and the construction of engineered strains, the development of new bacterial mosquito-killing preparations and the assessment of the environmental safety of wild-type and recombinant microorganisms, etc., develop new biological control technologies, and establish and perfect biological control Integrated control system for mosquitoes based on arboviruses.

---

**From:** Asher, David (b)(6) >  
**Sent:** Sunday, December 27, 2020 7:13 PM  
**To:** Pease, Michael (b)(6); DiNanno, Thomas G (b)(6); Feith, David (b)(6); Gibbs, Jeffrey J (b)(6); Couch, Johnny N (b)(6)  
**Cc:** Wright, Janey F (b)(6); Jih, Rongsong (b)(6)  
**Subject:** Re: Initial analysis of Baric emails: May/June US-China VTC's on COVID-19

(b)(5)

Thanks very much!

---

**From:** Pease, Michael (b)(6)  
**Sent:** Sunday, December 27, 2020 12:46 PM  
**To:** DiNanno, Thomas G (b)(6); Feith, David (b)(6); Gibbs, Jeffrey J (b)(6); Couch, Johnny N <CouchJN@state.gov>  
**Cc:** Wright, Janey F (b)(6); Jih, Rongsong (b)(6); Asher, David (b)(6)  
**Subject:** Initial analysis of Baric emails: May/June US-China VTC's on COVID-19

(b)(5)

(b)(5)

○ **Scientists from China and US Share Experience in COVID-19 Prevention and Control**

About 30 scientists from China and the United States held an online dialogue to share their experience in COVID-19 prevention and control and opinions on the prevention of future pandemic on May 12th and 14th (Beijing time). The virtual dialogue was jointly organized by the Chinese Academy of Sciences (CAS), the National Academy of Sciences (NAS) and the National Academy of Medicine (NAM). Participants shared their experience in fighting against COVID-19 and exchanged views on such topics as clinical issues related to treatment and management of patients, and limiting the spread of COVID-19 and steps towards restarting society.

COVID-19, an infectious disease caused by the most recently discovered coronavirus, has so far spread to 216 countries, areas and territories, with over 4.5 million confirmed cases and claiming 300 thousand deaths globally, according to the World Health Organization. "The pandemic will not really be controlled in any country, until it is ultimately controlled in every country. So it's in our mutual interest to do our best to learn as rapidly and as effectively as we can from one another," said Dr. Harvey Fineberg, President of the Gordon and Betty Moore Foundation, one participant of the dialogue.

Experts taking part in the dialogue agreed that it is of great importance to have a discussion to promote exchanges between the scientific communities of the two countries. "It's an extension of a dialogue that's been going between scientists in China and the U.S. We are very happy to be able to continue this dialogue in this time when actually all the work we are doing becomes very important," said Diane Griffin, Vice President of NAS, in the dialogue. Dr. George F. Gao, convener from the Chinese side, Director-General of the Chinese Center for Disease Prevention and Control, said, "This is a great dialogue. We hope that both sides

could continue to organize dialogues like this, and contribute to the global efforts in fighting against the COVID-19 pandemic from the scientific perspective."

- Notable participants included Baric, Daszak, Shi and Yuan (WIV leaders)
- The agenda items listed below speak volumes IMHO given:
  - This is the first such exchange we are aware of, six months into a devastating pandemic and the US is still struggling with these questions
  - Discussion of such critical and sweeping issues is limited to a 6-hour exchange between a couple dozen US and PRC personnel
  - The PRC has continued to prevent direct access to raw data and collaboration between scientists.
  - The only alternative has been to wait for PRC-government sanctioned academic papers and misleading press releases to emerge.

- Issues discussed:

#### Day 1

Introductory remarks and group introductions

- China situational overview

- U.S. situational overview

Clinical Issues Related to Treatment and Management of Patients

Clinical manifestations of COVID-19 disease:

- What range of clinical, end-organ, organ, and other body system manifestations of disease has been documented in China

Influence of Patient Characteristics:

- How did patient age, gender, general health condition, or other characteristics influence the efficacy of drugs, NPIs, or best practices?

- How was this determined?

Protection of Medical Personnel:

- What measures have proven most effective in [text not recovered by OCR]

Drug Treatments:

- What has been the Chinese experience with developing drug treatments or using existing drugs in treatment of patients, from prophylaxis to pre-symptomatic patients to patients with severe symptoms?

Non-pharmaceutical Interventions:

- Were effective non-pharmaceutical interventions (NPIs) for patient care identified?

- Were there other best practices for management of COVID-19 patients that emerged from the pandemic experience?

Immune plasma:

- What is China's experience in using immune plasma or other antibody-based therapies in the treatment of COVID-19 patients or prevention of further spread of disease?

Lessons Learned:



o Were other lessons learned from China's pandemic experience that should be applied to future staffing and equipping of hospitals or other patient care facilities?

Future Collaboration:

o What are the most fruitful areas of future scientific collaborations between our countries in this area?

Day 2

Viral shedding:

o What is the degree of shedding among pre-symptomatic/asymptomatic individuals?

o Do recovered patients continue to shed infectious virus? If yes, for how long?

o Has post-infection viral shedding been demonstrated to result in new infections?

o Has an explanation regarding pathogenesis leading to apparent recrudescence of disease in previously positive, then negative patients been arrived at?

Immune response:

o How is immune response being measured? Is it via binding assays versus neutralization tests, use of antibody assays in diagnosis of acute disease and as an indicator of protection?

o Was there standardization of your testing tools?

o Immunity: After recovery, do patients have immunity? How protective is this immunity?

o Is there indication of persistence of such immunity?

Vaccines:

o Has the Chinese research community made progress in the development of COVID-19 vaccines?

Exposure routes:

o Has progress been made in understanding the routes of exposure to COVID-19 air, water, and surfaces, both indoors and outdoors?

Contact with Animals:

o Would increased surveillance of or interventions to reduce contact with pets, wild, or livestock animal species help limit the future spread of COVID-19 or other coronaviruses?

Halting Spread:

o What measures have proven most effective in halting viral spread in China?

Preventing a Fall Resurgence:

o What steps should be taken in anticipation of a fall resurgence in transmission?

Reestablishing Normality:

o What lessons has China learned about returning society and the economy to a "normal" state?

Future Collaboration:

o What are the most fruitful areas of future scientific collaborations between our countries in this area?

Day 3 (June 9)

Immune Response and Immunotherapy

o Use of antibody assays in diagnosis of acute disease and as an indicator of protection

o How is immune response being measured?

o Was there standardization of testing tools?

o What is the overall situation of serologic investigation in the US?

o What can be said about the characterization of the

Innate immune responses?

humoral immune response?

cellular immune response?

o What is China's experience in using immune plasma or other antibody-based therapies for COVID-19 patients and for prevention of infection?

o Is the use of immune plasma effective?

o Have there been any complications?

o What has been China's experience with human monoclonal antibodies for treatment and prevention?

o Do a majority of the monoclonal antibodies isolated from patient B cells produce neutralizing antibodies?

o What immunopathologies are evident in the patients with COVID-19?

o Are there any biomarkers in patients who develop systemic inflammation?

o What is the most effective treatment for patients who develop a cytokine storm?

Immunity

o After recovery, what types of antiviral immune responses are present?

o Do these immune responses protect from re-infection?

o What is known about the durability of neutralizing antibody and longevity of protective immunity?

o Did recovery from SARS provide any protection from infection with SARS-CoV-2?

o Progress in the development of vaccine in the U.S. especially mRNA vaccine?

Reactivation or Reinfection of Recovered Patients, Fall resurgence

o Has reactivation of latent virus or re-infection been seen among survivors?

o Is reactivation/reinfection a concern with respect to a fall resurgence?

o What steps should be taken in anticipation of a fall resurgence in transmission?

o What is the COVID-19 prevention and control strategy in the US for the second half of this year?

o When do you expect COVID-19 vaccine to be available in the U.S.?

- Chinese Participants included

- Zhu Chen: Dr. Zhu Chen is president of the Red Cross Society of China, CAS member. He was previously minister of the National Health Commission of China. (Only available on the 14th)

- George F. Gao: Dr. George F. Gao is Director-General of CCDC, a professor at the CAS Institute of Microbiology, CAS member.

- Dongfeng Gu: Dr. Dongfeng Gu is vice president of Southern University of Science and Technology, CAS member.

- Hualiang Jiang: Dr. Hualiang Jiang is currently a professor at CAS Shanghai Institute of Materia Medica (SIMM), CAS member. He was previous director of SIMM, and now he is the chairman of the Scientific Committee of the institute. His research focuses on drug discovery and development. (Only available on the 12th)

- Lanjuan Li: Dr. Lanjuan Li is a physician and professor in infectious diseases, a member of the Chinese Academy of Engineering. She is currently director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. (Only available on the 12th)
- Zhengli Shi: Dr. Zhengli Shi is a professor at CAS Wuhan Institute of Virology.
- Chen Wang: Dr. Chen Wang is vice president and a member of the Chinese Academy of Engineering, and president of the Chinese Academy of Medical Sciences. (Only available on the 14th)
- Guiqiang Wang: Dr. Guiqiang Wang is a professor at the Peking University First Hospital and is president of the Society of Infectious Diseases, Chinese Medical Association. (Only available on the 12th)
- Haiming Wei: Dr. Haiming Wei is a professor at the University of Science and Technology of China.
- Zhiming Yuan: Dr. Zhiming Yuan is a professor at CAS Wuhan Institute of Virology, Director of Wuhan P4 lab.
- Yongqing Zhang: Dr. Yongqing Zhang is Deputy Director-General of CAS Bureau of Frontier Sciences and Education, a professor at CAS Institute of Genetics and Developmental Biology. (Only available on the 12th)
- Guoping Zhao: Dr. Guoping Zhao is a professor at CAS Shanghai Institutes for Biological Sciences, CAS member.
- Qi Zhou: Dr. Qi Zhou is Deputy Secretary-General of CAS, Director of CAS Institute of Zoology, CAS member. (Only available on the 12th)
  
- US Participants included
  - Ralph Baric: Dr. Ralph Baric, PhD, is a Professor in the Department of Epidemiology at the University of North Carolina's School of Public Health.
  - Peter Daszak: Dr. Peter Daszak, PhD, is president of EcoHealth Alliance, a nonprofit non-governmental organization that supports various programs on global health.
  - Victor Dzau: Dr. Victor Dzau, MD, is currently president of the U.S. National Academy of Medicine of the U.S. National Academy of Sciences, Engineering and Medicine. He was previously the president and CEO of Duke University Medical Center.
  - David Franz: Dr. David R. Franz, DVM, PhD, is currently retired, but served in the U.S. Army Medical Research and Materiel Command for 23 of 27 years on active duty and as Commander of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
  - Harvey Fineberg: Dr. Harvey Fineberg, MD, is currently president of the Gordon and Betty Moore Foundation, immediately prior to which he was President of the Institute of Medicine (now the National Academy of Medicine).
  - Diane Griffin: Dr. Diane Griffin, MD, PhD, is University Distinguished Service Professor in the W. Harry Feinstone Department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health and the current vice-president of the U.S. National Academy of Sciences.

- Peggy Hamburg: Dr. Margaret (Peggy) Hamburg, MD, is an American physician and public health administrator. She served as the 21st Commissioner of the U.S. Food and Drug Administration from May 2009 to April 2015 and is currently foreign secretary for the U.S. National Academy of Medicine.
- James Le Duc: Dr. James Le Duc, PhD, is the director of the Galveston National Laboratory, professor, Microbiology and Immunology and the John Sealy Distinguished Chair in Tropical and Emerging Virology, University of Texas Medical Branch, Galveston Texas.
- Stanley Perlman: Dr. Stanley Perlman, MD, PhD, is Professor of Microbiology and Immunology and of Pediatrics at the University of Iowa Health Care.
- David Relman: Dr. David Relman, MD, PhD is a microbiologist and the Thomas C. and Joan M. Merigan Professor in Medicine and in Microbiology & Immunology at the Stanford University School of Medicine.
- Linda Saif: Dr. Linda J. Saif, PhD, is Distinguished University Professor, Department of Veterinary Preventive Medicine, Food Animal Health Research Program, Ohio Agricultural Research and Development Center of the Ohio State University.
- Pei-Yong Shi: Dr. Pei-Yong Shi, PhD, is I.H. Kempner Professor of Human Genetics, University of Texas Medical Branch, Galveston Texas.

---

**From:** Pease, Michael

**Sent:** Saturday, December 26, 2020 5:17 PM

**To:** DiNanno, Thomas G (b)(6) >; Feith, David (b)(6) >; Gibbs, Jeffrey J (b)(6) >; Couch, Johnny N (b)(6) >

**Cc:** Wright, Janey F (b)(6) >; Jih, Rongsong (b)(6) >; Asher, David (b)(6)

**Subject:** Baric UNC FOIA Emails Update

First, the bad news: UNC's or Baric's lawyers did what most lawyers do when responding to FOIA requests - i.e., they purposefully converted all emails to low resolution image files. This makes it very hard to convert them back to usable text. Consequently we get a higher percentage of misidentified letters, numbers and symbols (aka "noise") during the OCR process.

Now for the good news: The techs at Sayari did a great job of OCRing the huge set of PDF image files, although there is still a significant amount of noise in the text to contend with. From the resulting 89 raw text files (76MB) I was able to isolate at least 2,141 emails within about 200 threads spanning dates from October 2017 through 30 July 2020.

Of note, as highlighted below:

- Baric was involved in hundreds of "Red Dawn" emails about the pandemic involving USG officials starting around 22 January.
- It appears that there may have been at least three virtual meetings involving Baric with Chinese scientists in May and June (will take a look at those emails).
- (b)(5)

- (b)(5)

More to follow.

Here is a summary table of unique subject lines/threads harvested from the text files:

Thread Subject Text	Emails	Days	Earliest Thread Email	Latest Threat Email	Found In
Collaborative coronavirus discussion invitation	1	1	1/10/2017	1/10/2017	1-1-1000.txt
nice work !!!!!!!	2	1	2/15/2017	2/15/2017	1-1-1000.txt
Zika in SE Asia	1	1	4/19/2017	4/19/2017	1-1-1000.txt
Nido2017 invited speakers	1	1	4/25/2017	4/25/2017	1-1-1000.txt
Professorship Virology, Berlin	1	1	5/10/2017	5/10/2017	1-1-1000.txt
Nido2017 Oral Presentation	1	1	5/26/2017	5/26/2017	1-1-1000.txt
Nido2017 Group Photo	1	1	6/7/2017	6/7/2017	1-1-1000.txt
Nido2017 Gala Dinner	1	1	6/8/2017	6/8/2017	1-1-1000.txt
Nido2017 Gala Dinner at the Grand Hall	1	1	6/8/2017	6/8/2017	1-1-1000.txt
Thank you for attending Nido2017	1	1	6/15/2017	6/15/2017	1-1-1000.txt
CETR Program Information	1	1	6/23/2017	6/23/2017	1-1-1000.txt
Nido2017 Photo Gallery	1	1	7/3/2017	7/3/2017	1-1-1000.txt
IDEA team photo	1	1	7/13/2017	7/13/2017	1-1-1000.txt
NBIC Biosurveillance Presentation Series	9	6	7/13/2017	7/18/2017	1-1-1000.txt
NBIC Biosurveillance Presentation Series info for presenters	2	2	7/18/2017	7/19/2017	1-1-1000.txt
Talk	2	1	7/19/2017	7/19/2017	1-1-1000.txt
Virology Special Issue Presubmission Deadline is Aug 18, 2017	1	1	8/14/2017	8/14/2017	1-1-1000.txt
CEPI invitation to vaccine R&D pipeline and cost tracking survey against epidemic infectious diseases	1	1	9/27/2017	9/27/2017	1-1-1000.txt
NAS GNL invitation to participate in a meeting of U.S. and Chinese experts, Jan 16-18 2018	1	1	11/2/2017	11/2/2017	1-1-1000.txt
NAS mtg in Galveston	2	2	11/10/2017	11/11/2017	1-1-1000.txt
RFA-AI-17-042: Centers of Excellence for Translational Research (CETR)	1	1	12/1/2017	12/1/2017	1-1-1000.txt
Flight arrangements to Galveston for NAS/Chinese Academy meeting Jan. 16-18	7	3	12/18/2017	12/20/2017	1-1-1000.txt
Happy Holidays from Virologica Sinica!	1	1	12/22/2017	12/22/2017	1-1-1000.txt
US-China meeting in Galveston	2	3	1/3/2018	1/5/2018	1-1-1000.txt

Agenda and travel info for upcoming Galveston, Texas meeting	1	1	1/12/2018	1/12/2018	1-1-1000.txt
Two tenure track assistant professor positions at Duke-NUS EID	1	1	1/17/2018	1/17/2018	1-1-1000.txt
Thank You!	2	1	1/19/2018	1/19/2018	1-1-1000.txt
EcoHealth Alliance - W9	1	1	1/24/2018	1/24/2018	1-1-1000.txt
Nice meeting you in Galveston and invitation to Wuhan meeting in October 2018	2	1	2/7/2018	2/7/2018	1-1-1000.txt
Ralph's upcoming visit	1	1	2/23/2018	2/23/2018	1-1-1000.txt
trip to New York	2	1	3/6/2018	3/6/2018	1-1-1000.txt
"Baric Dinner" has been canceled.	1	1	3/6/2018	3/6/2018	1-1-1000.txt
"Baric Dinner" has been canceled.	1	1	3/6/2018	3/6/2018	1-1-1000.txt
[RESCHEDULED] Call with Peter - now on 3/15	1	1	3/12/2018	3/12/2018	1-1-1000.txt
dual use safety language	1	1	3/23/2018	3/23/2018	1-1-1000.txt
Visit to UNC	1	1	3/28/2018	3/28/2018	1-1-1000.txt
Invitation Letter for the 8th International Symposium on Emerging Viral Diseases	5	140	4/14/2018	8/31/2018	1-1-1000.txt
visit	1	1	4/23/2018	4/23/2018	1-1-1000.txt
Information for ICEID 2018 Plenary and Panel Speakers	1	1	8/10/2018	8/10/2018	1-1-1000.txt
Thank you for speaking at ICEID	2	1	8/30/2018	8/30/2018	1-1-1000.txt
Abstract for Wuhan meeting	1	1	9/24/2018	9/24/2018	1-1-1000.txt
International Symposium on Emerging Viral Diseases, Wuhan	4	10	9/30/2018	10/9/2018	1-1-1000.txt
Final Program of the 8th International Symposium on Emerging Viral Diseases	1	1	10/15/2018	10/15/2018	1-1-1000.txt
NASEM bio meetings in Harbin, China in Jan 2019?	4	4	11/13/2018	11/16/2018	1-1-1000.txt
Visa information for NAS January trip to Harbin, China	1	1	11/28/2018	11/28/2018	1-1-1000.txt
NASEM bio meetings in Harbin, China in Jan 2019 - update and conference call	1	1	12/11/2018	12/11/2018	1-1-1000.txt
NASEM bio meetings in Harbin, China in Jan 2019 - conference call on 12/18 at 2 PM ET	1	1	12/14/2018	12/14/2018	1-1-1000.txt
NASEM bio meetings in Harbin, China in Jan 2019 - conference call on 12/18 at 2 PM ET docs	2	1	12/17/2018	12/17/2018	1-1-1000.txt
NASEM bio meetings in Harbin, China in Jan 2019 - travel memo and final agenda	1	1	1/3/2019	1/3/2019	1-1-1000.txt
new call from DTRA	1	1	1/3/2019	1/3/2019	1-1-1000.txt
National Academies Travel Reimbursement: Harbin 2019 meeting	1	1	1/11/2019	1/11/2019	1-1-1000.txt

postdoctoral position available at the Virus Ecology Unit, Rocky mountain Laboratories, NIAID	1	1	1/14/2019	1/14/2019	1-1-1000.txt
National Academies Travel Reimbursement: Harbin 2019 meeting - docs and photos	1	1	1/17/2019	1/17/2019	1-1-1000.txt
Ralph's visit to Columbia	3	1	3/20/2019	3/20/2019	1-1-1000.txt
new coronavirus from Wuhan	6	2	1/9/2020	1/10/2020	1-1-1000.txt
Rg novel coronavirus	2	12	1/10/2020	1/21/2020	1-1-1000.txt
Wuhan outbreak	5	9	1/20/2020	1/28/2020	1-1-1000.txt
{EXTERNAL} 2019-nCoV	1	1	1/22/2020	1/22/2020	1-1-1000.txt
2019-nCoV	10	8	1/22/2020	1/29/2020	1-1-1000.txt
2019-nCoV	2	4	1/23/2020	1/26/2020	1-1-1000.txt
Wolverines 2019-nCoV Call	1	1	1/26/2020	1/26/2020	1-1-1000.txt
Red Dawn Call Listening Session 2019-nCoV Call	139	20	1/26/2020	2/14/2020	1-1-1000.txt 1-1001-2000.txt 1-2001-3000.txt 1-3001-4000.txt 1-4001-5000.txt 9-6001-7000.txt
2019-nCoV	18	3	1/28/2020	1/30/2020	1-1-1000.txt
Red Dawn: Wolverines 2019-nCoV Call is open	3	1	1/29/2020	1/29/2020	1-1-1000.txt
deadline question re: Virology paper/for publication in San Jose Mercury News/Bay Area News Group	1	1	1/30/2020	1/30/2020	1-1-1000.txt
Red Dawn Call Listening Session 2019-nCoV Call,	3	1	2/2/2020	2/2/2020	1-1-1000.txt
Red Dawn Call Listening Session 2019-nCoV Call	12	9	2/2/2020	2/10/2020	1-1-1000.txt 1-1001-2000.txt 1-2001-3000.txt
Reminder - Invitation to the Global Research and Innovation Forum: Towards a Roadmap for the 2019 Novel Coronavirus	1	1	2/3/2020	2/3/2020	1-1-1000.txt
2019-nCoV in kids--the dog that didn't bark	1	1	2/3/2020	2/3/2020	1-1-1000.txt
Reminder - Invitation to the Global Research and Innovation Forum: Towards a Roadmap for the 2019 Novel	1	1	2/3/2020	2/3/2020	1-1-1000.txt

{EXTERNAL} Red Dawn Call Listening Session 2019-nCoV Call	1	1	2/4/2020	2/4/2020	1-1001-2000.txt
URGENT: Please review by NOON if at all possible...	10	1	2/4/2020	2/4/2020	1-1-1000.txt 1-1001-2000.txt
Link to documents on prioritisation of vaccines documents	1	1	2/5/2020	2/5/2020	1-1001-2000.txt
please use -	1	1	2/5/2020	2/5/2020	1-1001-2000.txt
Thanks and News about the letter	1	1	2/7/2020	2/7/2020	1-1001-2000.txt
nCOV-2019	4	1	2/8/2020	2/8/2020	1-1001-2000.txt
nCoV-2019	3	1	2/8/2020	2/8/2020	1-1001-2000.txt
ACE/ACE2	1	1	2/10/2020	2/10/2020	1-2001-3000.txt
Red Dawn COVID-2019	5	1	2/13/2020	2/13/2020	1-3001-4000.txt
Isolation and Quarantine for HCWs	25	2	2/14/2020	2/15/2020	1-4001-5000.txt
Isolation and Quarantine for HCWS	4	2	2/14/2020	2/15/2020	1-4001-5000.txt
Flash!!! Red Dawn Call Saturday Air Evacuation--What Time works??	15	1	2/15/2020	2/15/2020	1-4001-5000.txt
Flash!! Red Dawn Call Air Evacuation Risk Mitigation Measures	2	1	2/15/2020	2/15/2020	1-4001-5000.txt
Flash!! Red Dawn Call Detection Kits, Disease Characterization	1	1	2/15/2020	2/15/2020	1-5001-5508.txt
Red Dawn Breaking, COVID-19	11	3	2/16/2020	2/18/2020	1-5001-5508.txt 2-2001-3000.txt
Red Dawn Breaking, COVID-19 Collaborative, Feb 16	15	7	2/16/2020	2/22/2020	1-5001-5508.txt 2-1-1000.txt 2-2001-3000.txt
Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start	137	9	2/16/2020	2/24/2020	1-4001-5000.txt 1-5001-5508.txt 2-1-1000.txt 2-1001-2000.txt



					2-2001-3000.txt
Time to chat about coronavirus?	3	2	2/17/2020	2/18/2020	1-4001-5000.txt
Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start --- Rapid testing vs Safe and compliant quarantine -	1	1	2/21/2020	2/21/2020	2-1-1000.txt
Red Dawn Breaking, COVID-19 Collaborative, Feb 16 start -- asymptomatic vs symptomatic, flu vs COVID-19	1	1	2/24/2020	2/24/2020	2-2001-3000.txt
Red Dawn Breaking Bad, Start	2	2	2/24/2020	2/25/2020	2-3001-4000.txt
Red Dawn Breaking Bad, Start Feb 24	121	7	2/24/2020	3/1/2020	2-2001-3000.txt 2-3001-4000.txt 2-4001-5000.txt 2-5001-6000.txt
Red Dawn Rising Start Feb 29	124	5	2/29/2020	3/4/2020	2-5001-6000.txt 2-6001-6093.txt 3-1-1000.txt
Restricted Wolverine Call Sunday Evening (today) at 8 PM EST	2	1	3/1/2020	3/1/2020	3-1-1000.txt
Updated Travel Policy and Meeting Guidelines in Response to Coronavirus	1	1	3/3/2020	3/3/2020	3-1-1000.txt
Red Dawn Rising Start Feb 29 -- Evidence of how NPI works --	1	1	3/4/2020	3/4/2020	3-1-1000.txt
Red	2	1	3/5/2020	3/5/2020	2-2001-3000.txt 3-5001-6000.txt
Red Dawn Raging Start March	6	8	3/5/2020	3/12/2020	3-5001-6000.txt 4-8001-9000.txt

<p>Red Dawn Raging Start</p>	<p>16</p>	<p>9</p>	<p>3/5/2020</p>	<p>3/13/2020</p>	<p>3-5001-6000.txt                      4-1-1000.txt                      4-1001-2000.txt                      4-13001-14000.txt                      4-2001-3000.txt                      4-3001-4000.txt                      6-1-1000.txt                      7-10001-11000.txt                      7-8001-9000.txt</p>
<p>Red Dawn Raging Start March 4</p>	<p>204</p>	<p>12</p>	<p>3/5/2020</p>	<p>3/16/2020</p>	<p>3-1-1000.txt                      3-1001-2000.txt                      3-2001-3000.txt                      3-3001-4000.txt                      3-4001-5000.txt                      3-5001-6000.txt                      3-6001-6626.txt                      4-1-1000.txt                      4-10001-11000.txt                      4-1001-2000.txt                      4-11001-12000.txt                      4-12001-13000.txt                      4-13001-14000.txt                      4-2001-3000.txt                      4-3001-4000.txt                      4-4001-5000.txt                      4-5001-</p>

					6000.txt 4-6001- 7000.txt 4-7001- 8000.txt 4-8001- 9000.txt 4-9001- 10000.txt 5-1-1000.txt 5-1001- 2000.txt 5-2001- 3000.txt 5-4001- 5000.txt 5-5001- 6000.txt 5-6001- 7000.txt 6-1-1000.txt 7-1-1000.txt 7-12001- 12178.txt
Dean Nelson and other admin at CVM were in/are still in Wash DC	1	1	3/6/2020	3/6/2020	3-1001- 2000.txt
[EXTERNAL) Red Dawn Raging Start March 4	15	5	3/8/2020	3/12/2020	3-1001- 2000.txt 3-2001- 3000.txt 3-3001- 4000.txt 3-4001- 5000.txt 4-3001- 4000.txt

[EXTERNAL] Red Dawn Raging Start March 4	45	9	3/8/2020	3/16/2020	3-1001-2000.txt 3-2001-3000.txt 3-3001-4000.txt 3-4001-5000.txt 4-2001-3000.txt 6-1001-2000.txt 6-3001-4000.txt 7-10001-11000.txt 7-1001-2000.txt 7-3001-4000.txt 7-4001-5000.txt 7-6001-7000.txt 7-8001-9000.txt
[EXTERNAL] Red Dawn Raging Start	2	1	3/9/2020	3/9/2020	3-3001-4000.txt
Red Dawn Raging, Start March 4	4	1	3/10/2020	3/10/2020	3-4001-5000.txt
[EXT] Red Dawn Raging Start March 4	2	1	3/12/2020	3/12/2020	4-1-1000.txt
Epidemiologist needed	1	1	3/13/2020	3/13/2020	4-6001-7000.txt
Singapore's measures to contain COVID-19	11	2	3/15/2020	3/16/2020	5-4001-5000.txt 7-8001-9000.txt
Impact of Social Distancing Practices	1	1	3/16/2020	3/16/2020	7-12001-12178.txt
Red Dawn Responding, Start 16	2	2	3/16/2020	3/17/2020	8-1-1000.txt
[EXTERNAL] Red Dawn	4	5	3/16/2020	3/20/2020	7-10001-11000.txt 9-1-1000.txt 9-1001-2000.txt

Red Dawn Responding, Start 16 March	91	15	3/16/2020	3/30/2020	10-4001-5000.txt 7-12001-12178.txt 8-1-1000.txt 8-1001-1670.txt 9-1-1000.txt 9-1001-2000.txt 9-2001-3000.txt 9-4001-5000.txt 9-5001-6000.txt
Social Distancing	1	1	3/17/2020	3/17/2020	8-1-1000.txt
No reinfection and titer data in COVID Plasma	4	1	3/18/2020	3/18/2020	8-1-1000.txt
COVID Plasma	1	1	3/18/2020	3/18/2020	8-1-1000.txt
CONFIRMED - COVID-19 Conversations Webinar Series Advisory Group Meeting	1	1	3/18/2020	3/18/2020	8-1-1000.txt
Has everyone seen this?	2	1	3/19/2020	3/19/2020	8-1001-1670.txt
NPI New Statistical Analysis Study	1	1	3/19/2020	3/19/2020	8-1001-1670.txt
The psychological impact of quarantine and how to reduce it	3	1	3/19/2020	3/19/2020	9-1-1000.txt
[EXTERNAL] Red Dawn Reflux,	1	1	3/19/2020	3/19/2020	9-1-1000.txt
Have you seen this article on hydroxychloroquine and azithromycin tx	2	1	3/19/2020	3/19/2020	8-1001-1670.txt
[EXTERNAL] Red Dawn Reflux, Start	2	1	3/19/2020	3/19/2020	9-1-1000.txt 9-1001-2000.txt
[EXTERNAL] Red Dawn Reflux,	5	2	3/19/2020	3/20/2020	9-1001-2000.txt 9-2001-3000.txt
[EXTERNAL] Red Dawn Reflux, Start 2020 0319, 10:35	5	2	3/19/2020	3/20/2020	9-1-1000.txt 9-1001-2000.txt
[EXTERNAL] Red Dawn Reflux, Start 2020	6	2	3/19/2020	3/20/2020	9-1-1000.txt 9-1001-2000.txt

[EXTERNAL] Red Dawn Reflux, Start 2020 0319,	5	2	3/19/2020	3/20/2020	9-1-1000.txt 9-2001-3000.txt
[EXTERNAL] Red Dawn Reflux, Start 2020 0319, 10:35 EDT	69	4	3/19/2020	3/22/2020	8-1001-1670.txt 9-1-1000.txt 9-1001-2000.txt
Red Dawn Reflux, Start 2020 0319, 10:35 EDT	11	5	3/19/2020	3/23/2020	8-1001-1670.txt 9-1001-2000.txt 9-2001-3000.txt
[EXTERNAL] Red Dawn Reflux, Start 2020 0319, 10:35 EDT	12	5	3/19/2020	3/23/2020	9-1-1000.txt 9-1001-2000.txt 9-2001-3000.txt
[EXTERNAL] Red	2	1	3/20/2020	3/20/2020	9-1-1000.txt 9-1001-2000.txt
Update & action items - NAM-APHA COVID-19 Webinar Series	8	2	3/21/2020	3/22/2020	9-1-1000.txt 9-1001-2000.txt
Webinar topic	1	1	3/22/2020	3/22/2020	9-1001-2000.txt
Red Dawn Suppression, Start Mar 23, 10:00	1	1	3/23/2020	3/23/2020	9-2001-3000.txt
Red Dawn Suppression, Start Mar	2	1	3/23/2020	3/23/2020	9-2001-3000.txt
BWIRP Files	4	1	3/23/2020	3/23/2020	9-2001-3000.txt
The Science of Social Distancing: A free webinar from NAM and APHA	4	2	3/23/2020	3/24/2020	9-2001-3000.txt
Inquiry on Interest and Availability to Participate in INR Analytic Exchange on Scientific Evidence on Origins of Novel	7	3	3/23/2020	3/25/2020	9-2001-3000.txt 9-3001-4000.txt
Red Dawn Suppression, Start Mar 23, 10:00 EDT	83	5	3/23/2020	3/27/2020	9-1001-2000.txt 9-2001-3000.txt 9-3001-4000.txt 9-4001-

					5000.txt 9-5001- 6000.txt
FDA announcement	1	1	3/24/2020	3/24/2020	9-2001- 3000.txt
*** China Data Dr. Michael Joyner***	1	1	3/25/2020	3/25/2020	9-2001- 3000.txt
*** China Data   Dr. Michael Joyner**	1	1	3/25/2020	3/25/2020	9-2001- 3000.txt
[EXTERNAL] ***China Data Dr. Michael Joyner***	2	1	3/25/2020	3/25/2020	9-2001- 3000.txt
***China Data Dr. Michael Joyner***	2	1	3/25/2020	3/25/2020	9-2001- 3000.txt
***China Data   Dr. Michael Joyner***	2	1	3/25/2020	3/25/2020	9-2001- 3000.txt
Reuse of N95 Masks	5	2	3/25/2020	3/26/2020	9-3001- 4000.txt
Red Dawn Pondering, Start Mar 27, 15:45	42	16	3/27/2020	4/11/2020	9-5001- 6000.txt 9-6001- 7000.txt
CONFIRMED: Second advisory call for COVID-19 webinar series	1	1	3/28/2020	3/28/2020	9-5001- 6000.txt
[EXTERNAL] Red Dawn Pondering, Start Mar 27, 15:45	2	1	3/29/2020	3/29/2020	9-5001- 6000.txt
Red Dawn Pondering, Start Mar 27,	2	1	3/29/2020	3/29/2020	9-5001- 6000.txt
Masks	10	4	3/29/2020	4/1/2020	9-5001- 6000.txt
updates - NAM-APHA webinar series	1	1	3/31/2020	3/31/2020	9-5001- 6000.txt
Red Dawn Rooster, Start April 2, 17:00	29	6	4/2/2020	4/7/2020	9-5001- 6000.txt 9-6001- 7000.txt
Red Dawn Rolling, Start April 6, 15:00	35	6	4/6/2020	4/11/2020	9-6001- 7000.txt
Advisory Group Call: NAM-APHA COVID-19 Webinar Series	7	87	4/6/2020	7/1/2020	10-5001- 6000.txt 10-6001- 7000.txt

Health, Safety & Store Updates â€” The Latest from Kroger	2	4	4/7/2020	4/10/2020	9-6001-7000.txt
Health, Safety & Store Updates - The Latest from Kroger	2	4	4/7/2020	4/10/2020	9-6001-7000.txt
NAM-APHA COVID-19 Webinar Series Update	2	1	4/9/2020	4/9/2020	9-6001-7000.txt
Red Dawn	3	32	4/12/2020	5/13/2020	10-5001-6000.txt 4-12001-13000.txt 9-6001-7000.txt
Red Dawn Breaking Debacle - How can we help those at risk?	1	1	4/13/2020	4/13/2020	9-6001-7000.txt
Red Dawn Setting, Begin 13 April 08:00	60	23	4/13/2020	5/5/2020	10-1-1000.txt 10-1001-2000.txt 10-2001-3000.txt 9-10001-11000.txt 9-13001-14000.txt 9-15001-16000.txt 9-6001-7000.txt 9-7001-8000.txt 9-8001-9000.txt 9-9001-10000.txt



Red Dawn Setting, Begin 13April 08:00	176	24	4/13/2020	5/6/2020	10-1-1000.txt 10-1001-2000.txt 10-2001-3000.txt 10-3001-4000.txt 9-10001-11000.txt 9-11001-12000.txt 9-12001-13000.txt 9-13001-14000.txt 9-14001-15000.txt 9-15001-16000.txt 9-16001-16505.txt 9-6001-7000.txt 9-7001-8000.txt 9-8001-9000.txt 9-9001-10000.txt
Update on Health Data Security	1	1	4/14/2020	4/14/2020	9-7001-8000.txt
Red Dawn Setting, Begin 13 April	4	2	4/14/2020	4/15/2020	9-7001-8000.txt 9-8001-9000.txt
Red Dawn Setting, Begin	8	13	4/14/2020	4/26/2020	10-1-1000.txt 9-11001-12000.txt 9-12001-13000.txt 9-8001-9000.txt
talk on the phone?	7	3	4/16/2020	4/18/2020	9-7001-8000.txt

					9-8001-9000.txt
Red Dawn Setting, Begin 13April	3	3	4/20/2020	4/22/2020	10-1-1000.txt
Drug repurposing screen paper	2	1	4/22/2020	4/22/2020	9-10001-11000.txt
questions from leadership group	1	1	4/22/2020	4/22/2020	9-10001-11000.txt
interesting paper	4	1	4/22/2020	4/22/2020	9-10001-11000.txt
New paper	2	1	4/23/2020	4/23/2020	9-10001-11000.txt
background for NAM-APHA advisory group call tomorrow	4	15	4/23/2020	5/7/2020	10-3001-4000.txt 9-11001-12000.txt 9-13001-14000.txt
NIAID COVID strategic plan	1	1	4/24/2020	4/24/2020	9-10001-11000.txt
2020 April 25 Daily COVID-19 LST Report (Red Dawn Setting, Begin 13April 08:00]	1	1	4/26/2020	4/26/2020	9-12001-13000.txt
Register Now! Webinar on Can old drugs take down a new coronavirus? The state of COVID-19 drug repurposing efforts	1	1	4/27/2020	4/27/2020	9-12001-13000.txt
Register Now! Webinar on Can old drugs take down a new coronavirus? The state of COVID-19 drug repurposing	2	1	4/27/2020	4/27/2020	9-12001-13000.txt
Direct observation of repeated infections with endemic coronaviruses	13	2	4/28/2020	4/29/2020	9-13001-14000.txt
apropos "warp speed" vaccine development	1	1	4/30/2020	4/30/2020	9-14001-15000.txt
Just in: Compilation of RECS	1	1	4/30/2020	4/30/2020	9-14001-15000.txt
INVITIVION: virtual U.S. China dialogue meeting on COVID-19	1	1	5/3/2020	5/3/2020	10-1-1000.txt
Paul H. Lambert recommends as speaker in the webeninar: IABS webinar on COVID, MAY 27: upfdate Information, with	1	1	5/4/2020	5/4/2020	10-1001-2000.txt
lecture on COVID-19 animal models by Emmie de Wit, NIAID, on May 6 at 3:00 p.m.	2	1	5/4/2020	5/4/2020	10-1001-2000.txt
Paul H. Lambert recommends as speaker in the webeninar: IABS webinar on COVID, MAY 27: upfdate Information,	2	2	5/4/2020	5/5/2020	10-1001-2000.txt

Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7	11	7	5/4/2020	5/10/2020	10-1001-2000.txt 10-3001-4000.txt
Red Dawn Posturing, Begin May 5, 12:50 EDT	84	49	5/5/2020	6/22/2020	10-2001-3000.txt 10-3001-4000.txt 10-4001-5000.txt 10-5001-6000.txt
Paper of interest	3	1	5/6/2020	5/6/2020	10-3001-4000.txt
webinar on extreme weather and COVID-19	9	8	5/8/2020	5/15/2020	10-3001-4000.txt 10-4001-5000.txt
Re. List of Chinese participants - Virtual U.S. China dialogue meeting on COVID-19: planning discussion on May 7	1	1	5/11/2020	5/11/2020	10-3001-4000.txt
Virtual U.S. China dialogue meeting on COVID-19: ZOOM link for first call	1	1	5/11/2020	5/11/2020	10-3001-4000.txt
Virtual U.S. China dialogue meeting on COVID-19: final docs, Zoom link (and back up phone number)	4	1	5/11/2020	5/11/2020	10-3001-4000.txt
Virtual U.S. China dialogue meeting on COVID-19: final docs	1	1	5/12/2020	5/12/2020	10-3001-4000.txt
Virtual U.S. China dialogue meeting on COVID-19: Zoom link for Wednesday May 13 call 9pm et	9	3	5/12/2020	5/14/2020	10-3001-4000.txt
Red Dawn Posturing, Begin May 5, 12:50	2	2	5/13/2020	5/14/2020	10-4001-5000.txt
Red Dawn Posturing, Begin May 5,	2	2	5/13/2020	5/14/2020	10-5001-6000.txt
***CCPP19: Early safety preprint posted on medRxiv***	1	1	5/14/2020	5/14/2020	10-3001-4000.txt
[EXTERNAL] Your preprint 10.1101/2020.05.12.20099879 has posted on medRxiv	1	1	5/14/2020	5/14/2020	10-3001-4000.txt
Follow up Meeting to Discuss Results of the Virtual U.S. China dialogue meeting on COVID-19	6	5	5/14/2020	5/18/2020	10-4001-5000.txt
Nice interview with Cat Lutz	4	1	5/15/2020	5/15/2020	10-4001-5000.txt
SARS-COV-2 NHP Research Publications	1	1	5/20/2020	5/20/2020	10-4001-5000.txt

SARS-CoV-2 NHP Research Publications	3	1	5/20/2020	5/20/2020	10-4001-5000.txt
3rd Virtual U.S. China dialogue meeting on COVID-19	3	3	5/20/2020	5/22/2020	10-4001-5000.txt
background for tomorrow's NAM-APHA advisory group call	2	1	5/21/2020	5/21/2020	10-4001-5000.txt
Reaching out to Red Dawn team members	2	1	5/25/2020	5/25/2020	10-4001-5000.txt
3rd Virtual U.S. China dialogue meeting on COVID-19 Tuesday, June 9, 9-11PM ET	11	10	6/1/2020	6/10/2020	10-4001-5000.txt
ZOOM link 3rd Virtual U.S. China dialogue meeting, Tuesday, June 9, 9-11PM ET	4	6	6/4/2020	6/9/2020	10-4001-5000.txt
[SUSPICIOUS MESSAGE] Agenda & background for NAM-APHA advisory group call at 2 pm	1	1	6/5/2020	6/5/2020	10-4001-5000.txt
Agenda & background for NAM-APHA advisory group call at 2 pm	2	1	6/5/2020	6/5/2020	10-4001-5000.txt
June 10   Daily COVID-19 LST Report	2	2	6/10/2020	6/11/2020	10-5001-6000.txt
Join us for a Conversation with California's COVID-19 Testing Task Force Leaders on Friday, June 26th	1	1	6/22/2020	6/22/2020	10-5001-6000.txt
Red Dawn Posturing, Update on California Testing Task Force Webinar Friday 26 June, 4-	1	1	6/23/2020	6/23/2020	10-5001-6000.txt
Red Dawn Posturing, Update on California Testing Task Force Webinar Friday 26 June, 4-5 PM EDT	3	3	6/23/2020	6/25/2020	10-5001-6000.txt
Red Dawn Posturing	3	6	6/25/2020	6/30/2020	10-5001-6000.txt
Red Dawn Rhapsodizing Begin July 2, 2020	61	25	7/2/2020	7/26/2020	10-6001-7000.txt 10-7001-7245.txt
Op-Ed - Treat COVID19 as though it were airborne - until we prove that it is not	5	2	7/14/2020	7/15/2020	10-6001-7000.txt
July 20   Daily COVID-19 LST Report	2	2	7/20/2020	7/21/2020	10-6001-7000.txt
COVID-19 Conversations: K-12 School Reopening Webinar - Draft Agenda	2	3	7/21/2020	7/23/2020	10-6001-7000.txt
[EXTERNAL] Your preprint 10.1101/2020.07.29.20162917 has posted on medRxiv	2	1	7/30/2020	7/30/2020	10-7001-7245.txt
Preprint 10.1101/2020.07.29.20162917 has posted on medRxiv	1	1	7/30/2020	7/30/2020	10-7001-7245.txt

**Sender:** "Wright, Janey F" (b)(6)

Asher, David (b)(6)

Jih, Rongsong (b)(6)

Pease, Michael (b)(6)

**Recipient:** DiNanno, Thomas G (b)(6);

Feith, David (b)(6);

Gibbs, Jeffrey J (b)(6);

Couch, Johnny N (b)(6)